Metformin has previously shown the therapeutic potentials in a HFD-induced NAFLD animal model, and the clinical application actually improves the serum levels of ALT and the partial histological changes [30,31]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.